Obesity
Conditions
Brief summary
Normalizing weight gain and preventing the redistribution of body fat is a major health issue, and could help prevent the onset of various symptoms of metabolic syndrome. Above all, it is important to understand the mechanisms by which these different treatments affect adipose tissue. To this end, the investigators will first study the impact of GLP-1 analogues on adipose tissue. The main objective is to show that subjects treated with a GLP-1 agonist have a significant change in their oxytocin levels compared with subjects not treated with a GLP-1 agonist.
Interventions
OTHERBlood GLP1
On the day of surgery, the surgeon will remove visceral adipose tissue (1 cm3) from the operative waste. The adipose tissue is separated into 2 samples, one frozen in nitrogen, the other embedded in formalin. The samples are then sent to the Institut de Biologie de Valrose (iBV) to assess any differences between the two groups of patients (patients treated with anti-GLP-1 analogues
OTHERBlood No treated GLP1
On the day of surgery, the surgeon will remove visceral adipose tissue (1 cm3) from the operative waste. The adipose tissue is separated into 2 samples, one frozen in nitrogen, the other embedded in formalin. The samples are then sent to the Institut de Biologie de Valrose (iBV) to assess any differences between the two groups of patients (patients treated with patients not treated with anti-GLP-1 analogues) and the presence of fibrosis.
Sponsors
Centre Hospitalier Universitaire de Nice
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient over 18 years of age. * Patient able to read and understand the information/consent leaflet. * Patient with BMI \> 35 with at least one comorbidity. Or BMI \> 40 * Indication for digestive surgery validated in a multidisciplinary consultation meeting and prior agreement accepted by the CPAM. * Membership of a social security scheme * Patient's signed informed consent * For subjects in the GLP-1 analogue group: GLP-1 analogue taken for at least 3 months. * For non-GLP-1 analogue group: never taken GLP-1 analogues.
Exclusion criteria
* Pregnant or breast-feeding women. * Vulnerable patients (under guardianship) * Patients deprived of liberty
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of oxytocin | one time (before surgery) | show that subjects treated with a GLP-1 agonist have a significant change in oxytocin levels compared with subjects not treated with a GLP-1 agonist. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Fibrosis rate | At surgery | compare adipose tissue caracteristics between patients treated by analog GLP1 and not treated by analog GLP1 |
Countries
France
Contacts
CONTACTROUX Christian, PhD
CONTACTIannelli Antonio, PhD
PRINCIPAL_INVESTIGATORIannelli Antonio, PhD
Clinique Parc Impérial, Service de Chirurgie Digestive
Outcome results
None listed